Drug Trial Radar · NCT01475721
SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.
Last checked: Nov 19, 2026Latest source record: Aug 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11,751
Actual
Start
Nov 18, 2011
Primary completion
Jun 23, 2015
Study completion Jun 23, 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Nov 21, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in adolescents and adults (12 years of age and older) taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone. ADVAIR™ and FLOVENT™ are trademarks of the GlaxoSmithKline Group of Companies.
Conditions
- Asthma
Interventions
ADVAIR 100/50mcgDrug
fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
ADVAIR 250/50mcgDrug
fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
ADVAIR 500/50mcgDrug
fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
FLOVENT 100mcgDrug
fluticasone propionate (100) twice daily (AM and PM) for 6 months
FLOVENT 250mcgDrug
fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
FLOVENT 500mcgDrug
fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)Time frame: From Day 1 up to 26 weeks
- Number of Participants Experiencing at Least One Asthma ExacerbationTime frame: From Day 1 up to 26 weeks
Locations
808 sites in 33 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Athens, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Florence, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Montgomery, Alabama
GSK Investigational Site
Pell City, Alabama
GSK Investigational Site
Scottsboro, Alabama
GSK Investigational Site
Toney, Alabama
GSK Investigational Site
Tuscaloosa, Alabama
GSK Investigational Site
Chandler, Arizona
GSK Investigational Site
Flagstaff, Arizona
GSK Investigational Site
Goodyear, Arizona
GSK Investigational Site
Green Valley, Arizona
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Mesa, Arizona
GSK Investigational Site
Peoria, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Sierra Vista, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Dinuba, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Granada Hills, California
GSK Investigational Site
Harbor City, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
Huntington Park, California
GSK Investigational Site
Lomita, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
Showing 40 of 808 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.